Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effect of intramuscular treatment with different iron dextran dosages and non-inferiority study to gleptoferron.
Acta Vet Scand
January 2025
Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Grønnegårdsvej 2, 1870, Frederiksberg C, Denmark.
Background: Prevention of iron deficiency in suckling piglets by intramuscular injection of a standardized amount of iron dextran or gleptoferron in the first days of life can lead to over- or underdosage with respective health risks. Currently, combined iron products containing an active substance against coccidia are also used on farms. When using a combination product targeting two diseases, an adjustment of the necessary amount of iron to prevent anaemia in the frame of a farm-specific treatment protocol is not possible.
View Article and Find Full Text PDFLandscape analysis of adverse events and dose intensity for FDA approved oncology small molecules.
Cancer Chemother Pharmacol
January 2025
Clinical Pharmacology and Translational Sciences, Pfizer Worldwide R&D, 10555 Science Center Drive, San Diego, CA, 92121, USA.
As development of new oncology small molecule therapies is focused mainly on molecularly targeted agents, the dose selection paradigm has shifted from the maximum tolerated dose (MTD)-based approach traditionally utilized with cytotoxic drugs towards determining an optimal dose with long-term tolerability while maintaining efficacy. To assess overall tolerability in recently approved oncology small molecules, we surveyed 54 compounds approved by the FDA since March 2017 with respect to dose intensity, dose modifications, and treatment emergent adverse events (TEAEs). Of the 54 new molecular entities surveyed, only 15 were approved at a label dose equal to the MTD (Label Dose = MTD).
View Article and Find Full Text PDFImmunoadsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders - A retrospective multicentre study.
Eur J Paediatr Neurol
December 2024
Department of Paediatric Nephrology, Gastroenterology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany. Electronic address:
Background: Therapeutic apheresis (TA) are promising treatment option for neuroimmunological disorders. In paediatrics, the available data is limited, particularly for the use of IA. The aim of this study was to analyse the use of PE and IA in children and adolescents, with emphasis on outcome and neurological course after treatment as well as the safety of the two modalities.
View Article and Find Full Text PDFSARS-CoV-2 Diversity and Transmission on a University Campus across Two Academic Years during the Pandemic.
Clin Chem
January 2025
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, United States.
Background: Institutions of higher education (IHE) have been a focus of SARS-CoV-2 transmission studies but there is limited information on how viral diversity and transmission at IHE changed as the pandemic progressed.
Methods: Here we analyze 3606 viral genomes from unique COVID-19 episodes collected at a public university in Seattle, Washington from September 2020 to September 2022.
Results: Across the study period, we found evidence of frequent viral transmission among university affiliates with 60% (n = 2153) of viral genomes from campus specimens genetically identical to at least one other campus specimen.
Practical guidelines for developing digital health solutions to increase equity in dementia care in the UK.
Front Digit Health
December 2024
London School of Hygiene and Tropical Medicine Uganda Research Unit, Medical Research Council (Uganda), Entebbe, Uganda.
Background: Digital Healthcare Solutions (DHS) are transforming healthcare by improving patients' experiences, safety and quality of care. However, despite all the proposed and observed advantages of DHS, a growing body of research suggests that these DHS are not equally accessible to all. This research aimed to assess whether equity frameworks for digital health solutions can be used to guide the development of digital health solutions to increase access to care for dementia patients in the UK and, thereafter, develop practical guidelines to guide the design of equitable DHS products to address this growing issue.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!